According to filings with the U.S. Securities and Exchange Commission, Nuclein is raising up to $15,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Nuclein
Nuclein, LLC was founded in 2017 by experienced biotechnology entrepreneurs Alan Blake and Dr. Richard Crockett. The companys mission is to create a hand-held, disposable, all-in-one, self-test for infectious disease testing, which delivers battery-powered, sample-to-answer results within one hour, without the need to mail in a sample. The company is headquartered in Austin, Texas.

To learn more about Nuclein, visit http://www.nuclein.com/
Nuclein Linkedin Page: https://www.linkedin.com/company/nucleindx/

Contact:
Alan Blake, Chief Executive Officer
512-879-3301
https://www.linkedin.com/in/alanrblake/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.